Log in

Relevant bibliographies by topics / Measles virus, vaccine, humoral immune response, cellular immune response

Contents

Journal articles

Academic literature on the topic 'Measles virus, vaccine, humoral immune response, cellular immune response'

Author: Grafiati

Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Measles virus, vaccine, humoral immune response, cellular immune response.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Measles virus, vaccine, humoral immune response, cellular immune response"

1

Lin, Wen-Hsuan, Chien-Hsiung Pan, Robert Adams, et al. "Route of immunization influences the induction of humoral, cellular and protective immunity by live attenuated measles vaccine in rhesus macaques (52.11)." Journal of Immunology 184, no. 1_Supplement (2010): 52.11. http://dx.doi.org/10.4049/jimmunol.184.supp.52.11.

Full text

Abstract:

Abstract Measles is a leading cause of vaccine-preventable mortality worldwide. To facilitate vaccine distribution, aerosol immunization has been proposed, but the immune response induced, and protection afforded, by live attenuated measles virus (MV) vaccine (LAV) given by the respiratory route have not been systematically studied. Rhesus macaques were immunized with liquid or powder LAV through a nebulizer, an endotracheal tube, or parenterally by intramuscular injection. The method of immunization significantly influenced the induction of the humoral and cellular immune responses to LAV, bu

APA, Harvard, Vancouver, ISO, and other styles

2

Ovsyannikova, Inna G., Neelam Dhiman, Robert M. Jacobson, Robert A. Vierkant, and Gregory A. Poland. "Frequency of Measles Virus-Specific CD4+ and CD8+ T Cells in Subjects Seronegative or Highly Seropositive for Measles Vaccine." Clinical Diagnostic Laboratory Immunology 10, no. 3 (2003): 411–16. http://dx.doi.org/10.1128/cdli.10.3.411-416.2003.

Full text

Abstract:

ABSTRACT The protective effect of measles immunization is due to humoral and cell-mediated immune responses. Little is known about cell-mediated immunity (CMI) to measles vaccine virus, the relative contribution of CD4+ and CD8+ T cells to variability in such immune responses, and the immunologic longevity of the CMI after measles vaccination in humans. Our study characterizes cellular immune response in subjects seronegative or highly seropositive for measles vaccine immunoglobulin G-specific antibody, aged 15 to 25 years, previously immunized with two doses of measles-mumps-rubella II vaccin

APA, Harvard, Vancouver, ISO, and other styles

3

Toptygina, A. P., Yu Yu Andreev, M. A. Smerdova, A. Yu Zetkin, and T. G. Klykova. "Formation of humoral and cellular immunity to measles vaccine in adults." Russian Journal of Infection and Immunity 10, no. 1 (2020): 137–44. http://dx.doi.org/10.15789/2220-7619-foh-1334.

Full text

Abstract:

Despite adherence to the policy of mass measles vaccination in the majority of countries, this infection still remains far from being fully eradicated. Measles outbreaks are reported worldwide, when the vast majority of cases are recorded in subjects of 18—35 years of age. Studies on assessing measles IgG antibody level in different regions of Russia reveal increased percentage of measles seronegative subjects among young adults. Current study was aimed at investigating formation of humoral and cellular immunity after measles vaccination in seronegative adults aged 18 to 30 years old. There we

APA, Harvard, Vancouver, ISO, and other styles

4

Fitriah, Munawaroh, and Jusak Nugraha. "Immunogenicity Assessment on Clinical Trials of SARS-CoV-2 Vaccines." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 28, no. 2 (2022): 202–8. http://dx.doi.org/10.24293/ijcpml.v28i2.1975.

Full text

Abstract:

Various strategies for dealing with COVID-19 have been carried out since the WHO declared COVID-19 as an international health emergency. One of the preventive strategies is the development of vaccines. Various vaccines have been developed worldwide. As of April 13, 2021, there were 184 vaccine candidates in the pre-clinical phase and 16 vaccine candidates currently in phase III clinical trials using several platforms, such as inactivated viruses, vector viruses, and protein subunits, and mRNA. Clinical trials of the SARS-CoV-2 vaccine include a screening test consisting of thorough physical ex

APA, Harvard, Vancouver, ISO, and other styles

5

CZĘŚCIK, AGNIESZKA, MILENA DUNAL-SZCZEPANIAK, AGNIESZKA TRZCIŃSKA, and JOANNA SIENNICKA. "Response of Viral Specific CD4 T Cells to in vitro Stimulation with Vaccine and Wild Measles Virus Strains in Vaccinated and Naturally Infected Subjects." Polish Journal of Microbiology 63, no. 2 (2014): 203–9. http://dx.doi.org/10.33073/pjm-2014-026.

Full text

Abstract:

With the implementation of the WHO strategic plan for the elimination of measles, the number of measles cases in European Region has decreased. However, outbreaks are still observed. Although most measles cases affect unvaccinated individuals, cases with vaccinated persons are also reported. Furthermore, it was described that a high percentage of young people in Poland exhibit no presence of anti-MeV IgG despite the high level of vaccination covering no less than 97% of the Polish population. Strong evidence exists that immunity to measles is complex and depends on both the humoral and cellula

APA, Harvard, Vancouver, ISO, and other styles

6

Gerna, Giuseppe, Chiara Fornara, Milena Furione, and Daniele Lilleri. "Congenital Human Cytomegalovirus Infection: A Narrative Review of Maternal Immune Response and Diagnosis in View of the Development of a Vaccine and Prevention of Primary and Non-Primary Infections in Pregnancy." Microorganisms 9, no. 8 (2021): 1749. http://dx.doi.org/10.3390/microorganisms9081749.

Full text

Abstract:

Congenital cytomegalovirus infection (cCMV) may affect about 1% of all newborns all over the world as a result of either a primary or recurrent human cytomegalovirus (HCMV) infection. While about 90% of infants affected by cCMV are asymptomatic at birth, the remaining 10% are symptomatic often with neurodevelopmental impairment and sensorineural hearing loss. In view of identifying the best approach to vaccine prevention of cCMV, this review will examine the most important steps made in the study of the immune response to, and diagnosis of, HCMV infection. The maternal immune response and immu

APA, Harvard, Vancouver, ISO, and other styles

7

Witkowski, Wojciech, Sarah Gerlo, Evelien De Smet, et al. "Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population." Vaccines 10, no. 2 (2022): 260. http://dx.doi.org/10.3390/vaccines10020260.

Full text

Abstract:

Despite the high efficacy of the BNT162b2 vaccine in the general population, data on its immunogenicity among frail elderly individuals are limited. Recently, levels of anti-SARS-CoV-2 spike IgG antibodies and serum neutralization titers were confirmed as good immune markers of protection against the virus, with evidence showing a reverse correlation between these two parameters and susceptibility to infection. Here we analyzed sera from 138 nursing home residents (median age of 88.9 years) and 312 nursing home staff (median age of 50.7 years) to determine the humoral response to two doses of

APA, Harvard, Vancouver, ISO, and other styles

8

Olszewska, Wieslawa, Charalambos D. Partidos, and Michael W. Steward. "Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants." Infection and Immunity 68, no. 9 (2000): 4923–29. http://dx.doi.org/10.1128/iai.68.9.4923-4929.2000.

Full text

Abstract:

ABSTRACT Toxicity is a major factor limiting the development and use of potent adjuvants for human mucosally delivered vaccines. Novel adjuvant formulations have recently become available, and in the present study two have been used for intranasal immunization with a synthetic peptide immunogen (MAP-M2). This peptide represents a multiple antigenic peptide containing multiple copies of a mimotope M2, a peptide mimic of a conformational epitope of the fusion protein of measles virus. MAP-M2 was administered intranasally to experimental animals together with synthetic oligodeoxynucleotides conta

APA, Harvard, Vancouver, ISO, and other styles

9

Rodríguez Hernández, Carmen, and Juan Carlos Sanz Moreno. "Immunity against SARS-CoV-2: walking to the vaccination." Revista Española de Quimioterapia 33, no. 6 (2020): 392–98. http://dx.doi.org/10.37201/req/086.2020.

Full text

Abstract:

The coronavirus are a wide group of viruses among that the SARS-CoV-2 is included (family Coronaviridae, subfamily Coronavirinae, genus Betacoronavirus and subgenus Sarbecovirus). Its main structural proteins are the membrane (M), the envelope (E), the nucleocapsid (N) and spike (S). The immune response to SARS-CoV-2 involves the cellular and the humoral sides, with neutralizing antibodies fundamentally directed against the S antigen. Although the seroprevalence data are frequently assumed as protection markers, no necessarily they are. In Spain, it is estimated that, to assure the herd immuni

APA, Harvard, Vancouver, ISO, and other styles

10

Gracheva, Anastasiia V., Ekaterina R. Korchevaya, Roman V. Samoilikov та ін. "Аttenuation мarkers of cold-adapted SARS-CoV-2 variants". Medical academic journal 2, № 2 (2022): 79–88. http://dx.doi.org/10.17816/maj108725.

Full text

Abstract:

BACKGROUND: Unprecedented anti-epidemic measures and the widespread use of vaccines against COVID-19 have reduced the rate of hospitalization and mortality from the disease, but have not stopped the SARS-CoV-2 pandemic spread. The development of live vaccines against COVID-19, capable of providing the formation of a long-term humoral and cellular immune response and cross-protection against new SARS-CoV-2 variants of concern, is relevant. Previously at the I.I. Mechnikov Research Institute of Vaccines and Sera SARS-CoV-2 cold-adapted (ca, cold-adapted) variants were obtained. This work is aime

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!